Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BARDA Lays Out Vision For Next Pandemic: Vaccines For The US Within 130 Days

Executive Summary

Federal agency seeks dialogue with industry on how to enable surge capacity for pandemic vaccines without cutting back on other production.One key factor: workforce development.

You may also be interested in...

BARDA's Next-Pandemic Response Plan Relies On Warp Speed-Like Partnership

US pandemic response agency looks to partner with industry in advance of next pandemic through consortium patterned after the Defense Department’s Medical CBRN Defense Consortium, which played key role in Operation Warp Speed.

Global Supply Chain Scrutiny And Investment In Domestic Alternatives For US Drug Shortages

Pharmaceutical supply chains may grow less efficient and less risk prone as US government gets more involved to ensure availability of pandemic and essential medicines. But what about pediatric oncology medicines and other treatments that save lives even though they may not be considered essential?

For Next Pandemic, BARDA Proposes New Consortia For Rapid Response

HHS agency would expand on DOD consortium approach that delivered the COVID-19 vaccines to bring together private sector teams that could quickly defend the US against future infectious outbreaks. Plan also calls for working with commercial lenders for the capital required to expand production of medical countermeasures.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts